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and metastatic liver tumors. Percutaneous RFA for hepatic
neoplasm is a recent innovation, but the results of prelimi-
nary clinical series and animal studies are encouraging
and show that it is technically feasible and has minimal
morbidity [4–8].
Although RFA is effective in the treatment of hepato-
cellular carcinoma and liver metastasis, to the best of
our knowledge, its clinical efficacy in the treatment of
intrahepatic cholangiocarcinoma has not been reported.
The purpose of this paper is to describe our experience with
percutaneous ultrasound (US)-guided RFA in intrahepatic
cholangiocarcinoma and to report on the technique, its
complications, and efficacy.
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This study evaluated the clinical applications, treatment effects, and complications of percutaneous
ultrasound (US)-guided radiofrequency ablation (RFA) of intrahepatic cholangiocarcinoma. Ten patients
(6 men and 4 women) with histologically proven cholangiocarcinoma underwent US-guided percutaneous
RFA. Tumor diameters ranged from 1.9 to 6.8 cm. There were 12 sessions of RFA for 10 solitary
cholangiocarcinomas. Eight patients were treated at a single session and two patients had two treatment
sessions. The efficacy of RFA was evaluated using contrast-enhanced dynamic computed tomography
1 month after treatment and then every 3 months. Complete necrosis was defined as lack of contrast
enhancement of the treated region. There was complete necrosis in eight tumors. In two patients with
large tumors (4.7 and 6.8 cm in diameter), enhancement of residual tissue was observed after RFA treatment,
indicating residual tumor. Complete necrosis was seen in all five tumors (100%) with diameters of
3.0 cm or less, two of three tumors (67%) with diameters of 3.1–5.0 cm, and one of two tumors (50%)
with diameters of more than 5.0 cm. A large biloma was found in one patient after treatment. No serious
complications occurred in the other nine patients. In conclusion, percutaneous RFA is effective and
successful in the treatment of intrahepatic cholangiocarcinoma of 3 cm or less and satisfactory for tumors
of 3–5 cm. The rate of serious complications after RFA is low. Further follow-up is necessary to determine
long-term efficacy.
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Cholangiocarcinoma is the second most common primary
hepatic neoplasm [1]. Surgical resection of the tumor offers
the best chance for long-term survival. However, patients
with liver cirrhosis or chronic hepatitis are not candidates
for surgical resection because of poor hepatic reserve [2,3].
The alternative technique, radiofrequency ablation (RFA),
is a relatively new, minimally invasive therapy for primary
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MATERIALS AND METHODS
Patients
From January 2002 to October 2004, 10 patients under-
went percutaneous US-guided RFA to treat intrahepatic
cholangiocarcinoma. The study was approved by our
institutional review board, and informed consent was
obtained from all patients before the procedure. Of the 10
patients, two patients refused surgery and the other eight
were not considered surgical candidates because of
advanced age and either comorbid conditions (4 patients)
or poor hepatic reserve (4 patients). No tumors were located
near the intrahepatic great vessels.
There were six men and four women with a mean age of
66.2 years (range, 38–86 years) (Table). All 10 patients had
pathologic confirmation of the diagnosis from US-guided
biopsy performed, either in advance or at the time of RFA.
Tumor size ranged from 1.9 to 6.8 cm (mean, 3.4 cm).
Tumors were classified into three groups depending on
size: five tumors had a diameter of 3 cm or less, three tumors
were between 3.1 and 5 cm, and two tumors were larger
than 5 cm.
Radiofrequency tumor ablation technique
All patients were interviewed before treatment by one of
the two experienced interventional radiologists (Yi-You
Chiou, YYC; and Yi-Hong Chou, YHC), and were assessed
with US before the procedure to determine whether the
tumor was amenable to ablation under US guidance. Nine
patients received meperidine analgesia and one patient
was under conscious sedation (with droperidol, midazo-
lam and fentanyl), administered and monitored by
anesthesiologists.
Two different RFA devices were used with techniques
that have been described previously [9,10]: the RITA
(radiofrequency interstitial tissue ablation) device (Rita
Medical Systems, Mountain View, CA, USA) and the
Radionics device (Radionics, Burlington, MA, USA). With
the RITA device, ablation was performed using an expand-
able needle electrode (Starburst, 2–3 cm, or Starburst XL,
3–5 cm). With the Radionics device, treatment involved
either a cluster (three-prong, 2.5 cm active tip) or a single
(2 or 3 cm active tip) needle electrode, depending on the size
of the tumor. Each tumor received one to four ablations in
one session. The number of ablations performed in one ses-
sion was based on the size of the tumor.
Imaging assessment
After RFA, all patients underwent immediate follow-up US
or contrast-enhanced dynamic computed tomography (CT)
to evaluate the possibility of bleeding or fluid accumulation.
The efficacy of RFA was evaluated using contrast-enhanced
dynamic CT 1 month after treatment and then every 3
months. Treated tumors were assessed for residual tumor
and size changes. All follow-up images were also assessed
for the development of new metastatic disease and ancillary
peritumoral changes.
Residual disease was defined as persistent tumor without
necrosis in an area or areas after ablation, as determined at
the 1-month follow-up study. Recurrent disease was defined
as new tumor development after at least one imaging study
had demonstrated complete eradication of tumor. Assessment
of images was performed in consensus by three experienced
radiologists (YYC, YHC, and Jen-Huey Chiang).
Table. Demographic data of 10 patients with intrahepatic cholangiocarcinoma
Pre-RFA Post-RFA
CEA* CA19-9* CEA CA19-9
71 M S2 2.2 No 0.8 12.2 1.6 13.2
63 F S4 1.9 No 2.4 16.9 3.0 14.2
38 F S4 5.1 No 7.6 28.3 3.8 24.0
75 F S2–3 4.6 Yes 2.8 73.2 2.7 56.6
86 M S6 2.4 No ND ND ND ND
59 F S6–7 6.8 Yes 22.4 86.3 14.0 42.7
73 M S5 2.3 No ND ND 1.0 9.8
63 M S7 3.1 No ND ND ND ND
67 M S7 2.5 No 5.9 26.4 3.2 16.1
73 M S8 3.5 No ND ND 1.8 11.7
*Normal range: carcinoembryonic antigen (CEA) < 6.00 ng/mL; CA19-9 < 34.60 U/mL. ND = no available data.
Age (yr) Gender Location Size (cm)  Viable tumor
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RESULTS
There were 12 sessions of RFA for 10 solid hepatic tumors
in 10 patients. Eight patients were treated at a single session
and the other two had two treatment sessions. Six tumors
were located in the left hepatic lobe and four in the right
hepatic lobe. Four patients were treated with the RITA
device and six with the Radionics device. Of the patients
treated with the RITA system, one was treated with the
2–3 cm active electrode and three were treated with the
3–5 cm active electrode. Of the patients treated with the
Radionics system, one was treated with the 2 cm active tip
electrode, four with the 3 cm active tip electrode, and one
with the 2.5 cm cluster electrode.
The duration of follow-up ranged from 4 to 38 months
(mean, 20 months). Post-treatment CT showed total necrosis
in eight of 10 tumors (80%) after one or two sessions of RFA
(Figure). Residual tumor was observed in two patients with
larger tumors (4.6 and 6.8 cm in diameter). One of these two
patients died 14 months after percutaneous RFA. Complete
necrosis was seen in all five tumors (100%) with diameters
of 3.0 cm or less, two of three tumors (75%) with diameters
of 3.1–5.0 cm, and one of two tumors (50%) larger than 5.0
cm. One recurrent tumor was found 16 months later in one
patient with complete necrosis.
All patients tolerated the procedure with no major
complications. One patient had a large biloma after the pro-
cedure, which resolved after 6 months with percutaneous
drainage. Two patients had low-grade fever (< 38.5°C),
which resolved in 1 week without antibiotic treatment.
Two patients had pain or paresthesia around the puncture
site for several days after the procedure, which resolved
spontaneously in 2 and 4 weeks, respectively. All patients
received a prescription for pain medication (acetaminophen
or a non-steroidal anti-inflammatory drug) for 3–5 days
on discharge from hospital. No patient experienced the
postablative pain syndrome (pain, fever, malaise, and
leukocytosis) described after hepatic RFA, and no patient
received antibiotics before, during, or after the procedure.
DISCUSSION
Percutaneous RFA has been successfully used to treat liver
neoplasms [4–8,11,12]. Radiofrequency thermal ablation
works by converting radiofrequency waves into heat
through ionic vibration. Alternating current passing from
an electrode into the surrounding tissue causes ions to
vibrate in an attempt to follow the change in the direction of
Figure. A 63-year-old woman with biopsy-proven recurrent
cholangiocarcinoma in S4 of the left hepatic lobe. (A) Computed tomo-
graphy (CT) before surgery shows a 5 cm heterogeneous enhancing soft-
tissue mass (arrow) in the lateral segment of the left hepatic lobe.
(B) Unfortunately, 1 year after segmentectomy of the lateral segment, a
2 cm recurrent cholangiocarcinoma (arrow) is evident in S4 of the left
hepatic lobe. (C) CT 10 months after percutaneous ultrasound-guided
radiofrequency ablation shows no enhancement of the nodule (arrow).
 C
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the rapidly alternating current. It is the ionic friction that gen-
erates heat within the tissue and not the electrode itself. The
higher the current, the more vigorous the motion of the ions
and the higher the temperature reached over a period of
time, eventually leading to coagulation necrosis and cell
death. The purpose of RFA is to achieve local temperatures
that are lethal to the targeted tissue. Generally, thermal
damage to cells begins at 42°C; above 60°C, intracellular
proteins are denatured, the lipid layer melts, and irreversible
cell death occurs [13,14].
Although cholangiocarcinoma is generally considered
to be slow growing, surgical resection offers the best oppor-
tunity for improving long-term survival. Chemotherapy
and radiation have produced mixed results and are
considered adjunct treatments to surgical resection [15,16].
Intraluminal brachytherapy has been used within trans-
hepatic biliary stents for cholangiocarcinoma, but post-
treatment survival has generally been poor [15,17,18].
The traditional treatment for localized intrahepatic cho-
langiocarcinoma is surgical resection [18], but this method
is not ideal for all tumors because some patients are unable
or unwilling to undergo surgery or have limited functioning
hepatic tissue [19]. Attention has recently focused on RFA
as a minimally invasive treatment option for hepatic neo-
plasms, and various outcomes have been reported [14–18,20].
The length of hospital stay, treatment cost, and risk of com-
plications tend to be less with RFA than surgery.
The success rate of RFA in treating primary and metastatic
hepatic tumors is largely dependent on tumor size [15,17,18].
In our study, no tumors smaller than 3 cm had residual or
recurrent tumor on follow-up CT scans. Residual tumor was
found in the two patients with tumors greater than 5 cm after
a single session of RFA, and was still detected in one patient
after a second session of RFA. This suggests that larger tumors
are more difficult to completely eradicate with RFA. Other
factors that may affect the success rate of RFA are tumor
location and surrounding tissue. Centrally located tumors are
more difficult to treat successfully as a result of heat loss
caused by the extensive vascularity in the hepatic hilum.
During RFA, heat loss occurs at the needle tip mainly through
convection by means of blood circulation [13,14]. On the other
hand, surrounding fibrosis, as seen in cirrhotic patients [20], is
expected to reduce thermal conduction and heat dissipation,
thus improving the treatment effect.
A major advantage of RFA is the ability to avoid tract
bleeding and tumor seeding by coagulating the puncture tract
during electrode withdrawal. No hematoma or tumor seeding
after RFA was found in our study. The rate of serious com-
plications after RFA is low. Some studies show that RFA of
primary or metastatic hepatic tumors has a low complication
rate, around 4.6–13.1% [21–23]. One of our 10 patients (10%)
had a serious complication: a large biloma developed after
RFA, but it was totally resolved after 6 months with percu-
taneous drainage. Two patients had local pain or paresthe-
sia around the puncture site for several days or weeks, which
subsided spontaneously. This, presumably, was due to transient
damage to the intercostal or lumbar nerves in the affected
dermatome. Two patients had transient low-grade fever after
RFA, which resolved with oral analgesics. Other reported
complications are abscess, pneumothorax, peritoneal
hemorrhage, and acute cholecystitis, all of which can be treated
conservatively [21,22].
One limitation of our study is that the outcome of RFA was
judged by contrast enhancement on follow-up CT scan, with a
lack of enhancement implying that no viable tumor remained.
Lack of enhancement on follow-up imaging has generally been
assumed to mean lack of viable tumor [19]. If the tumors were
hypovascular on CT studies before RFA, we measured the den-
sity of the whole necrotic area after RFA to determine if there
remained persistent viable tumor. From our experience, it is
crucial to choose an ablation protocol and RFA electrode that
can create a necrosis zone large enough to achieve a sufficient
safety margin. We believe that lack of contrast enhancement
on CT indicates complete tumor eradication, but follow-up
surveillance imaging is warranted because long-term results
of RFA for cholangiocarcinoma are lacking, and later scans
should be used to detect local or metastatic lesions.
In conclusion, percutaneous US-guided RFA is a
technique of rapidly increasing usefulness. It allows safe
and effective treatment of hepatic tumors. As a minimally
invasive procedure, it is ideally suited for patients who are
not good surgical candidates. The success of RFA for
intrahepatic cholangiocarcinoma was primarily influenced
by the size of the tumor. RFA is a very promising technique
that is most successful in treating intrahepatic cholangio-
carcinoma smaller than 3 cm, and satisfactory in treating
tumors between 3 and 5 cm. Long-term follow-up data
regarding local and systemic recurrence and survival are
still needed, and will provide additional guidelines for the
most appropriate selection of patients suitable for this
treatment.
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